Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1 Dermatologic 1

Conditions

Skin Neoplasms 1 Recurrence 1 Neoplasms 1 Multiple Sclerosis, Relapsing-Remitting 1 Multiple Sclerosis 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Gliosarcoma 1 Glioblastoma 1 Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 41 Peripheral Blood Stem Cell Transplantation 40 fludarabine phosphate 36 Whole-Body Irradiation 27 Mycophenolic Acid 27 Tacrolimus 23 Busulfan 23 Cyclosporine 22 Antilymphocyte Serum 20 Etoposide 17 Methotrexate 16 Filgrastim 16 Melphalan 14 romidepsin 13 Radiotherapy 13 Flow Cytometry 12 Methylprednisolone 10 Brentuximab Vedotin 10 Therapeutics 9 Psychiatric Rehabilitation 9 Lenalidomide 8 pembrolizumab 7 fludarabine 7 Sirolimus 7 Rituximab 7 Bortezomib 7 Bexarotene 7 mogamulizumab 6 Polymerase Chain Reaction 6 Gemcitabine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma, T-Cell, Cutaneous × Dimethyl Fumarate × Clear all

NCT02546440 2023-03-31

DMF-CTCL

Universitätsmedizin Mannheim

Phase 2 Completed

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡